Literature DB >> 16476412

Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.

Elizabeth M Tunbridge1, Paul J Harrison, Daniel R Weinberger.   

Abstract

This review summarizes our current understanding of catechol-o-methyltransferase (COMT) and how it relates to brain function and schizophrenia. We begin by considering the COMT gene, its transcripts and proteins, and its relevance for central catecholamine function. We then describe how variation in COMT activity affects the function of the prefrontal cortex (PFC) and associated areas, reviewing evidence that COMT modulates executive function and working memory and highlighting recent data that also implicate it in emotional processing. Finally, we discuss briefly the genetic association between COMT and schizophrenia, focusing in particular on the complex interaction of functional loci within the gene that may underlie the mixed results of studies to date. We conclude by outlining preliminary data indicating that COMT is a promising therapeutic target for ameliorating the cognitive deficits associated with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476412     DOI: 10.1016/j.biopsych.2005.10.024

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  251 in total

1.  Predicting white matter integrity from multiple common genetic variants.

Authors:  Omid Kohannim; Neda Jahanshad; Meredith N Braskie; Jason L Stein; Ming-Chang Chiang; April H Reese; Derrek P Hibar; Arthur W Toga; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Paul M Thompson
Journal:  Neuropsychopharmacology       Date:  2012-04-18       Impact factor: 7.853

Review 2.  Genetics of emotion.

Authors:  Laura Bevilacqua; David Goldman
Journal:  Trends Cogn Sci       Date:  2011-08-10       Impact factor: 20.229

3.  Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.

Authors:  Doron Gothelf; Amanda J Law; Amos Frisch; Jingshan Chen; Omer Zarchi; Elena Michaelovsky; Renee Ren-Patterson; Barbara K Lipska; Miri Carmel; Bhaskar Kolachana; Abraham Weizman; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 4.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  COMT Val158Met and cognition: main effects and interaction with educational attainment.

Authors:  M-A Enoch; J F Waheed; C R Harris; B Albaugh; D Goldman
Journal:  Genes Brain Behav       Date:  2008-11-26       Impact factor: 3.449

Review 6.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

7.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

8.  Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.

Authors:  Ingrid Buchler; Daniel Akuma; Vinh Au; Gregory Carr; Pablo de León; Michael DePasquale; Glen Ernst; Yifang Huang; Martha Kimos; Anna Kolobova; Michael Poslusney; Huijun Wei; Dominique Swinnen; Florian Montel; Florence Moureau; Emilie Jigorel; Monika-Sarah E D Schulze; Martyn Wood; James C Barrow
Journal:  J Med Chem       Date:  2018-10-19       Impact factor: 7.446

9.  Relations between catechol-O-methyltransferase Val158Met genotype and inhibitory control development in childhood.

Authors:  Maureen E Bowers; George A Buzzell; Virginia Salo; Sonya V Troller-Renfree; Colin A Hodgkinson; David Goldman; Elena Gorodetsky; Jennifer Martin McDermott; Heather A Henderson; Nathan A Fox
Journal:  Dev Psychobiol       Date:  2019-08-01       Impact factor: 3.038

Review 10.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.